Gallery
May 24, 2022
FY 2022-23 is going to continue to be a tough year
Companies are looking at India not only to fill the gap in the supply chain but also prioritizing Indian suppliers.
May 24, 2022
We are progressively looking at reducing our carbon footprint says Rashesh Gogri, Vice Chairman & MD, Aarti Industries Ltd
We are looking at three buckets - Custom manufacturing, import substitutes and green & bio.
May 24, 2022
Freight rates to remain unstable for now: Dilip Shah, MD, Prakash Chemical
The current trends in the chemical industry is very volatile. There is a very good demand in the country. All the focus is shifted to India for many chemicals. Prices are too high and there are concerns with availability of raw materials. Freight rates have gone up due to congestion on Chinese ports.
May 24, 2022
We are moving towards green surfactant products manufacturing: Debashish Vanikar, Rossari Biotech
We see lot of demand emerging in India for Silicones.
May 24, 2022
Our capex target for FY 21-24 is Rs. 4,500-5,000 Cr : Rajendra V. Gogri, CMD, Aarti Industries Limited
Key milestones achieved by Aarti Industries in the chemicals and pharmaceuticals businesses during FY 2021-22?
AIL's (Aarti Industries Limited) journey was profound and exemplary in FY 2021-22. With our integrated value chain, diversified product mix, strong technical capabilities, and robust track record, the company emerged as a global partner of choice.
Some major milestones achieved by Aarti Industries during FY 2021-22 are:
- The company was conferred with the FICCI Company of the Era Award for its immense contribution to the chemical Industry in the past 25 years
- The company was conferred with a Gold Award in the 2021 EcoVadis CSR assessment, placing us among the top 5% of the companies assessed by EcoVadis. Our score improved from 60% in 2020 to 68% in 2021
- On the research and development front, we applied for 44 patents and were granted 11, out of which 8 were international patents
- The company was placed at 3rd position in the chemical sector (amongst 15 chemical companies) with an overall ESG score of 56. CRISIL evaluated independently Top 225 companies across 18 sectors based on their ESG assessment framework (as per information available in public domain) in FY21
- The company was awarded with the Responsible Care Logo post successful completion of RC Gap Assessment for self-imposed ethical commitment for better EHS&S performance and responsible management of chemicals throughout their lifecycle
- On the business front, the company successfully raised Rs. 1,200 crore additional share capital via QIP
- To meet growth aspirations, the company onboarded around 1,500 bright talents and created various growth avenues for internal talent, thereby accomplishing 18% internal growth transitions in FY22 from 12% in FY21
- The company also commissioned a speciality intermediate plant at Dahej for which a 20 year contract agreement was signed. The company also launched API intermediates block at pharmaceutical manufacturing unit in Vapi
- The company's CHRO was conferred as the HR Leader of the Year at the Economic Times Human Capital Awards 2021
The objective behind the company's move to demerge its pharma business to Aarti Pharmalabs. What's a long term strategy to strengthen the company's position in pharma?
The pharmaceutical division has been growing consistently over the past few years. The revenues for the pharmaceutical business have grown at a CAGR of 20% over a period of 5 years from Rs. 426 crore in FY17 to Rs. 872 crore in FY21. To create an overall value for our shareholders, and also to enable management of the company to focus and adopt the relevant strategies necessary for promoting growth and expansion, the demerger is being carried out. The demerger of pharma undertaking will facilitate a focused approach to the growth opportunities into respective segments, also enabling the segment to take strategic calls to capture these opportunities to grow.
Our long-term strategy is for enhancing the company's position in the pharmaceutical segment by focusing on adding new chemistries and value added products. We plan to add 50+ new products in the pharma division with a Capex of Rs. 350 - 500 crore. Strengthening our manufacturing capability, we plan to increase our manufacturing capacity by 1,200 KL with installation of 240 reactors under 10 manufacturing blocks in the next 5 years.
How will the newly operationalised Phase 2 Unit at Dahej SEZ help the company to diversify its agrochemical intermediates business?
The new chlorination unit at Jhagadia and specialty chemicals manufacturing unit at Dahej SEZ will cater to end use applications of polymer additives, agrochemicals, dyes pigments, and other speciality chemicals. The additional chlorination manufacturing capabilities will lead to growth in the company’s market share in the international market, further strengthening its position as Top 3 manufacturers globally in terms of product range. This will also provide an opportunity for forward integration. The facility will be ramped up over a period of next 3-4 years with a potential to generate an EBITDA of US $15 million.
For the Phase 2 unit at Dahej SEZ, we have already received proceeds of Rs. 630 crore as per the terms of the original contract. This unit has now been commissioned and we are planning to increase the capacity utilization to 80-90% in the next two years. With this facility, the Phase 2 unit at Dahej SEZ operational, our existing capacity for the intermediate has been expanded by almost 30 times. This chemical intermediate goes into multiple agro-technical applications as a herbicide and biocide. We plan to supply the intermediate to multiple customers involved in the manufacturing of the technical applications. With the incremental sales of this intermediate, we expect an addition of approximately US $40 million to the top line.
How is Aarti Research and Technology Centre (ARTC) at Navi Mumbai developing new innovations thereby helping create a robust product pipeline?
Aarti Research and Technology Centre (ARTC) is a state-of-the-art research facility, which has been set up to accelerate the development of new products driving future growth. Our R&D team has 200+ scientists for the chemical segment and has a strong analytical and process safety capabilities to support safe and efficient new product development. We are also working on setting up an engineering lab and an industrial biology lab at ARTC in the coming year. In the past couple of years, a total of 5,304 experiments have been conducted at ARTC. ARTC has been recommended for continued certification for ISO 27001:2013 Standard.
The objective of this research centre is to develop the most optimal and cost-effective process for a given product, with a primary emphasis on process safety and environmental impact. This has led us to develop some process innovations in the last 2 years and we have filed for provisional patents for some of these innovations. Our strategy is to create chemistry and technology platforms and our value-chain approach has enabled us to create a robust product pipeline to drive growth in future. In addition to ARTC, we have three more Research & Development centres located at Vapi and Dombivali. Our advanced analytical and process safety services offerings are now available for broader industries to specifically facilitate MSMEs.
What are the focus areas of Aarti's ESG initiatives and its reflection on the company product portfolio?
The company has conducted its materiality assessment in FY 2020-21 by interacting with its internal and external stakeholders to identify the focus areas. The focus areas are: Energy and carbon emission; water and effluent; occupational health and safety; compliance; human rights; and business ethics.
ESG has provided us with significant opportunities to optimize and expand our product portfolio. Our product portfolio will gradually increase with the products manufactured from less hazardous processes or green chemistry having minimal impact on the environment.
On the R&D front, the company is planning 40+ products for chemicals and 50+ products for pharmaceuticals. What’s your R&D plan for FY 2022-23?
In the chemical segment, our primary focus in FY23 is to develop and scale up products that form a part of our chlorotoluene value chain. We are developing capabilities in new chemistries such as photochlorination, ammoxidation and speciality fluorination. We are also working on some customer-specific projects that may reach the commercial stage in FY 2024-25. We are planning to invest more than Rs. 100 crore for Research & Development in the current financial year.
New verticals where you are focusing during FY 2022-23 and its impact?
For FY 2022-23, we are focussed on the development and execution of the chlorotoluene value chain. At the same time, we are working on creating long-term partnerships with global companies to manufacture in India. We plan to do this by leveraging our sustainability track record, value chain & chemistry platforms, and global trends such as the growing relevance of the China + 1 model. We are exploring opportunities in sunrise sectors such as battery and electronic chemicals and planning our foray into industrial biotechnology.
What is the Capex forecast for FY 2022-23 with respect to Chemicals and Pharmaceuticals? Projects where you are investing?
Our Capex target for FY 21-24 has been Rs. 4,500 - 5,000 crore of which Rs. 1,200 crore has been utilized in FY 2021-22 and the rest is planned to be spent in the coming couple of years. Some key Capex initiatives for these two years: USFDA capacities expansion at Tarapur for API units; Commencement of manufacturing unit for unit for 3rd long term contract at Jhagadia; Capacity expansion for NCB manufacturing facility at Vapi; and Expansion cum asset upgradation for Acid Unit at Vapi.
The company is also undertaking several expansions, asset restoration, and sustainability initiatives across existing facilities. The company is also in the process of adding Chlorotoluene range and other value added products (40+ products for chemicals and 50+ products for pharma).
The company is taking quantum lead on sustainability as the focus is on ‘Right chemistry for better tomorrow’. What are your FY 2022-23 plans for sustainability?
Our FY 2022-23 plans are focused on climate change issues. Aarti Industries is going for a quantum jump in reduction of its emissions through the use of renewables in its energy mix and other strategic initiatives. We are planning for more dual fired boilers (coal and biofuel). We have signed a contract for 13.5 Megawatts of hybrid renewable (solar and wind) sources of electricity. Through these initiatives, we will substantially reduce our carbon footprint.
We have planned several initiatives for enhancing the process safety across all our processes to make our operation intrinsically safe. We are also collaborating with business partners to imbibe ESG practices in their operations to ensure a sustainable supply chain.
Note: This interview has also been published on Chemical Industry Outlook 2022 and here's the link to view full version of the annual compendium.
May 11, 2022
Preventive maintenance and using AI to predict better models for customers is our mission: Lawrence Ng, VP, Sales - APJ, Aspen Technology
May 09, 2022
Doubling epoxy manufacturing capacity and expanding overseas operations: Jayant V. Dhobley, Business Head & CEO - Global Chemicals, Aditya Birla Group
April 27, 2022
Interview with Gaurav Bawa, Sr. Vice President, WIKA India Group
WIKA Instruments India Pvt. Ltd, established on September 2, 1997, is a wholly-owned subsidiary of WIKA Alexander Wiegand SE & Co. KG, Germany, a global market leader in pressure, temperature and level measurement technology. WIKA Instruments India has established and operates a quality and environment management system according to requirements of international standard (ISO 9001, ISO 14001).
December 26, 2021
We have seen a very good recovery in demand in H2 2021: Vikas Kulkarni, MD, Bostik India
Vikas Kulkarni, MD, Bostik India has over 25 years of experience and focuses on transforming the culture and performance of the organization through building organizational capability, robust strategies, and market access through strategic partnership & acquisition.
Kulkarni spoke exclusively to Pravin Prashant, Editor, Indian Chemical News on global trends and size of adhesives solutions segment, market size globally and India, Bostik market share, size of building & construction segment, size of industrial solution, size of disposable hygiene, new innovations and products, and 2022 plans.
What are the global trends in the adhesive solutions segment and how do you compare it with India?
The global growth in the adhesive solutions segment is 3 - 4% while in India it is in double digits. This high growth market means there are many opportunities for us to expand our presence, especially surfing on global trends such as: Construction Market - Energy efficiency, premium and performing solution, increase of DIY activities in emerging regions; and Industrial Adhesives - lightweight equipment and increase durability and sustainability, higher demand in electronics and batteries.
As the adhesive solutions segment of Arkema, we are in a unique position to stay connected to emerging trends in a variety of sectors and seize the emerging opportunities. In all those markets, we have strengthened our technologies and offerings in the past years and we are well positioned in all of them to keep growing, in India and around the world.
What is the size of the adhesive solutions market globally in 2021 and forecast for 2022?
The global adhesives solutions market in 2021 is €60 billion and the forecast is that it will reach €63 billion in 2022. We expect growth for all segments, with particularly strong drive for the Durable Goods and Construction segments, and promising prospects for the Packaging and Hygiene industries.
What is the size of the Indian adhesive solutions market in 2021 and forecast for 2022? What is the market share of Bostik in India and how do you plan to increase your market share?
Market size in India for adhesives & sealants is estimated at Rs. 15,000 crore. Bostik is the third top global player in the adhesives industry. In India, we are comparatively smaller since we do not currently participate in many market segments. However, in segments in which Bostik participates, we are among the top three players.
We are investing to grow our position in the market by strengthening our technologies, especially in the wake of the Fixatti and Ashland acquisitions to support our growth. In addition to this, acquisitions made by Bostik in the engineering adhesives space, positions us very well with technologies required in electronics and automotive segments. We have a clear plan to foray into these segments as also into consumer adhesives in 2022.
We have some hero products in each of these segments that we will bring into India. We will continue to invest in our talent, as we have done in the last two years to get the best in class people available to the industry. We will continue to invest in capital/assets as needed to expand our capacities and build new ones to support business growth. We also continue to look out for inorganic growth and strategic alliances to accelerate our growth.
Size of Indian adhesive solutions market for:
Building & construction segment
Tile Adhesives Tiling market is estimated to be around Rs. 1,200 crore. Market is at a very nascent stage of growth as almost 90% of the market is still using traditional sand, cement, mortar methods of application. However, we are witnessing a shift and expect the market to grow at a CAGR at 13% as a result of penetration conversion from traditional methods to bagged tile adhesives. Apart from this, the other solutions we offer to the B&C segments are WP, Repair Products & Sealants. Each of these markets is quite large and poised to continue to grow at 8-10%.
Industrial Solutions
The Indian adhesive market is estimated at around Rs. 9,000 crore, expected to grow at 11% per annum. The growth will vary across different segments. We see faster growth in Paper & Packaging, Hygiene, Automotive, and Energy and slightly lower growth in mature markets like Footwear and Construction. The Make in India campaign should give impetus to sectors like aerospace, defense, and electronics. Consumer adhesives is a huge market and it will continue to grow, benefiting from India’s demographics.
We have started seeing a trend towards sustainability with many customers looking for recyclable, biodegradable, low VOC and solvent free products. We, at Bostik, are gearing ourselves up to be ready with solutions that will be needed by the customer in the future.
Disposable hygiene segment
The market size is about Rs. 500 crore. It will grow in double digits in next few years, through penetration as disposable incomes go up in both urban and rural India. Industry is moving towards thin substrates to make end-products lighter. Bostik continues to innovate to meet changing needs for our customers.
What are the new innovations that the company is working on in global R&D labs? Please elaborate?
As the adhesive solutions segment of Arkema, we focus on creating innovative specialty adhesive solutions that contribute to a sustainable world. This means both: More sustainable adhesives, e.g. made out of recycled/bio sourced materials, which are themselves recyclable/compostable, which use less resources while they are produced, etc.; and smart adhesive solutions that help our customers reach their own sustainability goals, for instance by contributing to producing lighter and smaller objects, allowing better insulation to lower the carbon footprint of building, creating safer products, both for construction and hygiene; and enabling recyclability or composability of packaging.
This, and more, is what our global R&D labs are working on, alongside our business teams, clients and partners – Bostik’s culture of innovation is very much collaborative, even R&D at our lab is the result of a highly collaborative process.
How has the performance of Bostik India been in 2021 and what are your plans for 2022?
We have seen a very good recovery in demand in the second half of 2021 across all our business units. Raw material inflation has been a big challenge for the industry. The global supply chain disruption was another challenge to contend with. Overall, Bostik has been able to navigate these challenges quite well and continued to serve our customers.
We expect demand to continue to grow and some of the supply chain challenges to abate in 2022. Our plans for 2022 include expanding our footprint into some new segments like electronics, technical textile, and consumer. We will continue to innovate to meet changing customer requirements & bring the products that are sustainable to meet our own and customer’s sustainability goals.
Bostik has introduced a new series of GCR adhesive and sealant solutions called Silane-modified Sealant Products (SMPs) for the transport industry. Are you planning to launch these products in India?
We have launched the new GCR range to complement our existing top line products - SMP. The market is growing in India. SMP has low VOC and no Isocyanate making it environment friendly.
We cater to various applications in bus, metro and rail segments. As we launch the new Global Core range of products, we bring in the technology to address various other applications such as glazing, sheet metal bonding, and structural bonding. We have core experience on working with various OEMs across the globe and synergies will help us replicate here in India as well. With our wide range of sealants, we are also aiming at markets beyond transportation such as appliances and elevators.
December 22, 2021
Government should work on national chemical policy: Rajendra Gogri, CMD, Aarti Industries
Speaking on right policy measures, finalization of national chemical policy, extending PLI scheme, and custom tariff policy needs to be tailored at NextGen Chemicals & Petrochemicals Summit 2021